Recently, Zhejiang Daer Biotechnology Co., Ltd. (hereinafter referred to as "Daer Biotechnology"), a holding subsidiary of Huadong Medicine Co., Ltd. (hereinafter referred to as "the Company"), received the "Drug Clinical Trial Approval Notice" (Notice No.: 2026LP00516) issued by the National Medical Products Administration (NMPA). The clinical trial application for DR30206 for injection submitted by Daer Biotechnology was approved, with the indication being: this product in combination with standard chemotherapy, intended for patients with locally advanced or metastatic non-small cell lung cancer.
DR30206 for injection is a Class 1 therapeutic biological product independently developed by Daer Biotech and possessing global intellectual property rights. DR30206 is an antibody fusion protein targeting PD-L1, VEGF, and TGF-β; it restores the proliferation of exhausted CD8+ T cells by blocking the PD-1/PD-L1 signaling pathway; and reduces tumor angiogenesis and relieves immunosuppression by specifically binding to free VEGF and TGF-β, thereby achieving the goal of treating tumors. Completed non-clinical studies and ongoing Phase I clinical trials have shown that DR30206 has a clear mechanism of action and inhibits tumor growth, exhibiting good safety, which supports clinical trials of DR30206 in combination with standard chemotherapy in patients with locally advanced or metastatic non-small cell lung cancer.
The first clinical trial of DR30206 for injection in China was approved by the NMPA in June 2023 for the indication of advanced solid tumors, and in April 2025 it was approved for a clinical study of "in combination with standard chemotherapy for advanced or metastatic gastrointestinal tumors".
In December 2025, Daoer Bio submitted a clinical trial application to the NMPA for the treatment of patients with locally advanced or metastatic non-small cell lung cancer using DR30206 injection in combination with standard chemotherapy. The application was accepted and recently approved, allowing the product to conduct clinical trials.
To date, there are no antibody fusion protein drugs globally that simultaneously target PD-L1, VEGF, and TGF-β. The approval of this clinical trial in China for DR30206 injection in combination with standard chemotherapy for patients with locally advanced or metastatic non-small cell lung cancer represents another significant advancement in the drug's development. Moving forward, the company will continue to fully advance the clinical development and registration of this product, striving to provide more treatment options for patients!

https://mp.weixin.qq.com/s/R28esKEP_4oSCkbIBRJpAw